Skip to content

Evaluation of the efficacy and safety of two-step irradiance schedule in the treatment of condyloma acuminatum

Evaluation of the efficacy and safety of two-step irradiance schedule in the treatment of condyloma acuminatum

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044871
Enrollment
Unknown
Registered
2021-03-30
Start date
2021-03-30
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condyloma acuminatum

Interventions

experimental group:Two-step irradiance schedule
Control group:Conventional therapy

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Clinical diagnosed with condyloma acuminatum, 18 years old and over; 2.Warts located in the perianal area, distal urethra and external genitalia. 3.All patients are unfit and reluctant to undergo surgery for any reasons, and volunteered to participate in the study and ability to understand and the willingness to sign a written informed consent even when they were informed of alternatives. Patients are willing to pay for the treatment, and agreed to take a picture of the skin lesions.

Exclusion criteria

Exclusion criteria: 1.Patients have been treated with ALA-PDT and those who have applied any other impact study within 12 weeks; 2.Patients with other diseases that may affect the efficacy evaluation, such as other photodermatosis; 3.Patients taking phototoxic or photosensitive drugs within 12 weeks; 4.Patients with clinically and / or pathologically proven tumor invasion to other organs or tissues; 5.Patients with severe immune dysfunction; 6.Patients with scar constitution; 7.Patients with known skin photoallergy, porphyria or allergy to ALA, light or lidocaine; 8.Patients suffer from serious internal diseases, psychological and mental diseases.

Design outcomes

Primary

MeasureTime frame
Complete response rate of lesions at 1 month after treatment;

Secondary

MeasureTime frame
Pain assessment;Follow up the recurrence of lesions;

Countries

China

Contacts

Public ContactJiang Guan

The Affiliated Hospital of Xuzhou Medical University

dr.guanjiang@xzhmu.edu.cn+86 18052268168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026